Fentanyl, Dexmedetomidine

Phase 3Small molecule

UUniversity of Saskatchewan

Fentanyl, Dexmedetomidine is one of 43 small molecule programs targeting Amputation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmputationActive, not recruiting

Respiratory DepressionActive, not recruiting

AmputationPreclinical

Active, not recruiting

Respiratory DepressionPhase 3

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Amputation

#DrugCompanyPhaseTrials

Acanya

Pfizer

Approved

1 2

Ansaid

PPharmacia and Upjohn

Approved

1 3

Peridex

DDexcel Pharma Technologies Ltd.

Approved

1 4

Flagyl

DDePuy Orthopaedics

Approved

1 5

Teicoplanin

Sanofi

Approved

1 6

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Approved

2 7

Depakote

AbbVie

Phase 2

1 8

Co-Amoxiclav

IImperial College London

Approved

1 9

Iodine

UUniversity of California, Los Angeles

Approved

1 10

Xylocaine

MMEDRx USA, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Depression1 trial

Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy

Completed·UUniversity of Saskatchewan·Phase 3·NCT02987985·50 enrolled

Amputation1 trial

Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity

Recruiting·NNational Cancer Institute, Egypt·N/A·NCT07276867·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fentanyl, Dexmedetomidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fentanyl, Dexmedetomidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fentanyl, Dexmedetomidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Saskatchewan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Saskatchewan

Fentanyl, Dexmedetomidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Depression1 trial

Amputation1 trial

References

Drug Info

Quick Facts

Related News